A retrospective observational longitudinal medical chart review study of randomly sampled patients diagnosed with advanced/metastatic NSCLC. The minimum observational period for each patient will be 12 months.
Study Type
OBSERVATIONAL
Enrollment
382
Patient Demographics at diagnosis with advanced/metastatic NSCLC
Time frame: at baseline
Systemic treatments prescribed for NSCLC patients from treatment initiation through discontinuation
Time frame: approximately 12 months
Duration of systemic treatments
Time frame: approximately 12 months
Distribution of reasons for discontinuing treatment
Time frame: approximately 12 months
healthcare resource utilization in patients with advanced/metastatic NSCLC
NSCLC-related health care resources associated with the provision of systemic treatments and managing side effects of treatments: hospital admissions including emergency room visits
Time frame: approximately 12 months
Progression-Free Survival (PFS)
Time frame: approximately 12 months
Overall Survival (OS)
Time frame: approximately 12 months
Adverse Events (AEs)
Time frame: approximately 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.